Cannabinoids and neuroprotection

Cannabinoids and the Brain

Volumn , Issue , 2008, Pages 317-329

  Campbell, Veronica A ^a   Downer, Eric J ^b  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 70349734112     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-74349-3_15     Document Type: Chapter

References (81)

1. 1 cannabinoid receptor protects cultured mouse spinal neurons against excitotoxicity. Neuroscience Lett 309:197-201.
2. Bolshakov VY, Golan H, Kandel ER, Siegelbaum SA (1997) Recruitment of new sites of synaptic transmission during the cAMP-dependent late phase of LTP at CA3-CA1 synapses in the hippocampus. Neuron 19:635-651.
3. Berghuis P, Dobszay MB, Wang X, Spano S, Ledda F, Sousa KM, Schulte G, Ernfors P, Mackie K, Paratcha G, Hurd YL, Harkany T (2005) Endocannabinoids regulate interneuron migration and morphogenesis by transactivating the TrkB receptor. Proc Natl Acad Sci USA 102:19115-19120.
4. Bonfils PK, Reith J, Hasseldam H, Johansen FF (2006) Estimation of the hypothermic component in neuroprotection provided by cannabinoids following cerebral ischemia. Neurochem Int 49:508-518.
5. 1. Biochem J 312:637-641.
6. Butovsky E, Juknat A, Goncharov I, Elbaz J, Eilam R, Zangan A, Vogel Z (2005) In vivo upregulation of brain-derived neurotrophic factor in specific brain areas by chronic exposure to tetrahydrocannabinol. J Neurochem 93:802-811.
7. Campbell VA (2001) Tetrahydrocannabinol-induced apoptosis in cultured cortical neurones is associated with cytochrome c release and caspase-3 activation. Neuropharmacol 40:702-709.
8. 9- Tetrahydrocannabinol. J Neurosci 18:5322-5332.
9. Chen J, Lee CT, Errico S, Deg X, Cadet JL, Freed WJ (2005) Protective effects of tetrahydrocannabinol against NMDA-induced AF5 cell death. Brain Res Mol Brain Res 134:215-225.
10. Curran NM, Griffin BD, O'Toole D, Brady K, Fitzgerald SN, Moynagh PN (2005) the synthetic cannabinoid, R(+)WIN 55, 212-2 inhibits the interleukin-1 signaling pathway in human astrocytes in a cannabinoid receptor-independent manner. J Biol Chem 280:35797-35806.
11. Derkinderen P, Enslen H, Girault JA (1999) The ERK/MAP-kinases cascade in the nervous system. Neuroreport 10:24-34.
12. Derkinderen P, Ledent C, Parmentier M, Girault JA (2001) Cannabinoids activate p38 mitogenactivated protein kinases through CB1 receptors in hippocampus. J Neurochem 77:957-960.
13. Derkinderen P, Valjent E, Toutant M, Corvol JC, Enslen H, Ledent C, Trzaskos J, Caboche J, Girault JA (2003) Regulation of Extracellular Signal-Regulated Kinase by cannabinoids in hippocampus. J Neurosci 23:2371-2382.
14. Di Marzo V, Fontana A, Cadas H, Schinell S, Clmlno G, Schwartz J, Piomell D (1994) Formaton and inactivation of endogenous cannabinoid anandamide in central neurones. Nature 372:686-691.
15. 1 receptor-mediated c-Jun N-terminal kinase activation in cultured cortical neurons. Br J Pharmacol 140:547-557.
16. El-Remessy AB, Khalil IE, Matragoon S, Abou-Mohamed G, Tsai NJ, Roon P, Caldwell RB, Caldwell RW, Green K, Liou GI (2003) Neuroprotective effect of tetrahydrocannabinol and cannabidiol in NMDA-induced retinal neurotoxicity: Involvement of peroxynitrite. Am J Pathol 163:1997-2008.
17. Eposito G, De Filippis D, Maiuri MC, De Stefano D, Carnuccio R, Iuvone T (2006) Cannabidiol inhibits inducible NOS expression and NO production in β-amyloid-stimulated PC12 neurons through p38 MAP kinase and NFκB involvement. Neurosci Lett 399:91-95.
18. Eshhar N, Streim S, Biegon A (1993) HU-211, a non-psychotropic cannabinoid, rescues cortical neurones from excitatory amino acid toxicity in culture. Neuroreport 5:237-240.
19. Fernandez-Lopez D, Martinez-Orgado J, Nunez E, Romero J, Lorenzo P, Moro MA, Lizasoain I (2006) Characterization of the neuroprotective effect of the cannabinoid agonist WIN-55212 in an in vitro model of hypoxic-ischemic brain damage in newborn rats. Pediatr Res 60:169-173.
20. 1 cannabinoid receptor. Mol Pharmacol 62:1385-1392.
21. Galve-Roperh I, Aguado T, Rueda D, Velasco G, Guzman M (2002) Endocannabinoids: A new family of lipid mediators involved in the regulation of neural cell development. Curr Pharm Des 12:2319-2325.
22. Gilbert GL, Kim HJ, Waataja JJ, Thayer SA (2006) Tetrahydrocannabinol protects hippocampal neurons from excitotoxicity. Brain Res 128:61-69.
23. Gómez del Pulgar T, de Ceballos ML, Guzmán M, Velasco G (2002) Cannabinoids protect astrocytes from ceramide-induced apoptosis through the phosphatidylinositol 3-kinase/Protein Kinse B pathway. J Biol Chem 277:36527-36533.
24. Grewal SS, York RD, Stork PJS (1999) Extracellular-signal-regulated kinase signalling in neurons. Curr Opin Neurobiol 9:544-553.
25. Guzmán M, Sánchez C, Galve-Roperh I (2002) Cannabinoids and cell fate. Pharmacol Ther 95:175-184.
26. Hamelink C, Hampson A, Wink DA, Eiden LE, Eskay Rl (2005) Comparison of cannabidiol, antioxidants, and diuretics in reversing binge ethanol-induced neurotoxicity. J Pharmacol Exp Ther 314:780-788.
27. Hampson AJ, Grimaldi M, Axelrod J, Wink D (1998) Cannabidiol and (-)δ9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci USA 95:8268-8273.
28. Hansen HH, Ikonomidou C, Bittigau P, Hansen SH, Hansen HS (2001a) Accumulation of the anandamide precursor and other N-acylethanolamine phospholipids in infant rat models of in vivo necrotic and apoptotic neuronal death. J Neurochem 76:39-46.
29. Hansen HH, Schmid PC, Bittigau P, Lastres-Becker I, Berrendero F, Manzanare J, Ikonomidou C, Scmid HHO, Fernandez-Ruiz JJ, Hansen HS (2001b) Anandamide, but not 2-arachidonoylglycerol, accumulates during in vivo neurodegeneration. J Neurochem 78:1415-1427.
30. Hansen HS, Lauritzen L, Moesgaard B, Strand AM, Hansen HH (1998) Formation of N-acylphosphatidylethanolamines and N-acetylethanolamines proposed role in neurotoxicity. Biochem Pharmacol 55:719-725.
31. Haubrich C, Diehl R, Donges M, Schiefer J, Loos M, Kosinski C (2005) Recurrent transient ischemic attacks in a cannabis smoker. J Neurol 252:369-370.
32. Herlarr E, Brown Z (1999) p38 MAPK signaling cascades in inflammatory disease. Mol Med Today 5: 439-447.
33. Hollister LE (1986) Health aspects of cannabis. Pharmacol Rev 38:1-20.
34. Iuvone T, Esposito G, Esposito R, Santamaria R, Di Rosa M, Izzo AA (2004) Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on β-amyloidinduced toxicity in PC12 cells. J Neurochem 89:134-141.
35. Jackson SJ, Pryce G, Diemel LT, Cuzner ML, Baker D (2005) Cannabinoid-receptor 1 null mice are susceptible to neurofilament damage and caspase-3 activation. Neuroscience 134:261-268.
36. Jacobsson SOP, Rongard E, Stridh M, Tiger G, Fowler CJ (2000) Serum-dependent effects of tamoxifen and cannabinoids upon C6 glioma cell viability. Biochem Pharmacol 69:1807-1813.
37. Jin K, Xie L, Kim SH, Parmentier-Batteur S, Sun Y, Mao XO, Childs J, Greenberg DA (2004) Defective adult neurogenesis in CB1 caanbinoid receptor knockout mice. Mo Pharmacol 66:204-208.
38. Karanian DA, Brown QB, Makriyannis A, Bahr BA (2005a) Blocking cannabinoid activation of FAK and ERK1/2 compromises synaptic integrity in hippocampus. Eur J Pharmacol 508:47-56.
39. Karanian DA, Brown QB, Makriyannis A, Kosten TA, Bahr BA (2005b) Duel modulation of endocannabinoid transport and fatty acid amide hydrolase protects against excitotoxicity. J Neurosci 25:7813-7820.
40. 1 receptor ligands on lipid peroxidation and antioxidant defense systems in the rat brain. Pharmacol Rep 58:870-875.
41. Khaspekov LG, Brenz Verca MS, Frumkina LE, Hermann H, Marsicano G, Lutz B (2004) Involvement of brain-derived neurotrophic factor in cannabinoid receptor-dependent protection against excitotoxicity. Eur J Neurosci 19:1691-1698.
42. Kim SH, Won SJ, Mao XA, Jin K, Greenberg DA (2005) Involvement of protein kinase A in cannabinoid receptor-mediated protection from oxidative neuronal injury. J Pharmacol Exp Ther 313:88-94.
43. Kim SH, Won SJ, Mao XA, Jin K, Greenberg DA (2006a) Molecular mechanisms of cannabinoid protection from neuronal excitotoxicity. Mol Pharmacol 69:691-696.
44. Kim SH, Won SJ, Mao XA, Ledent C, Jin K, Greenberg DA (2006b) Role for neuronal nitricoxide synthase in cannabinoid-induced neurogenesis. J Pharmacol Exp Ther 319:150-154.
45. Lawston J, Borella A, Robinson JK, Whitaker-Azmitia PM (2000) Changes in hippocampal morphology following chronic treatment with the synthetic cannabinoid WIN 55, 212-2. Brain Res 877:407-410.
46. Louw DF, Yang FW, Sutherland GR (2000) The effect of δ-9-tetrahydrocannabinol on forebrain ischemia in rat. Brain Res 857:183-187.
47. Mackie K, Hille B (1992) Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cell lines. Proc Natl Acad Sci USA 89:3825-3829.
48. Maccarrone M, Lorenzon T, Bari M, Melino G, Finazzi-Agro A (2000) Anandamide induces apoptosis in human cells via vanilloid receptors. J Biol Chem 275:31938-31945.
49. 1. J Neurochem 80:448-456.
50. 1 receptors and on-demand defense against excitotoxicity. Science 302:84-88.
51. Matochik JA, Eldreth DA, Cadet JL, Bolla KI (2005) Altered brain tissue composition in heavy marijuana users. Drug Alcohol Depend 77:23-30.
52. Molina-Holgado F, Pinteaux E, Heenan L, Moore JD, Rothwell NJ, Gibson RM (2005) Neuroprotective effects of the synthetic cannabinoid HU-210 in primary cortical neurons are mediated by phosphatidylinositol 3-kinase/Akt signaling. Mol Cell Neurosci 28:189-194.
53. Monory K, Massa F, Egertova M, Eder M, Blaudzun H, Westenbroek R, Kelsch W, Jacob W, Marsch R, Ekker M, Long J, Rubenstein JL, Goebbels S, Nave KA, During M, Klugmann M, Wolfel B, Dodt HU, Zieglgansberger W, Wotjak CT, Mackie K, Elphick MR, Marsicano G, Lutz B (2006) Endocannabinoid system controls key epileptogenic circuits in the hippocampus. Neuron 51:455-466.
54. 6-tetrahydrocannabinol 1, 1-dimethylheptyl (HU-211) attenuates N-methyl-d-aspartate receptor-mediated neurotoxicity in primary cultures of rat forebrain. Neurosci Lett 162:43-45.
55. Nagayama T, Sinor AD, Simon RP, Chen J, Graham SH, Jin K, Greenberg DA (1999) Cannabinoids and neuroprotection in global and focal cerebral ishcemia and in neuronal cultures. J Neurosci 19:2987-2995.
56. Panikashvili D, Simeonidou C, Ben-Shabat S, Hanus L, Breuer A, Mechoulam R, Shohami E (2001) An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 413:527-531.
57. 1 cannabinoid receptors are involved in neuroprotection via NFκB. Blood Flow Metab. 25:477-484.
58. Panikashvili D, Shein NA, Mechoulam R, Trembolver V, Kohen R, Alexandrovich A, Shohami E (2006) The endocannabinoid, 2-AG, protects the blood-brain barrier after closed head injury and inhibits mRNA expression of proinflammatory cytokines. Neurobiol Dis 22:257-264.
59. Pahan K, Schmid, M (2000) Activation of NFκB in the spinal cord of experimental allergic encephalomyelitis. Neurosci Lett 287:17-20.
60. Polste BM, Fiskum G (2004) Mitochondrila mechanisms of neural cell apoptosis. J Neurochem 90:1281-1289.
61. Pryce G, Ahmed Z, Hankey DJ, Jackson SJ, Croxford JL, Pocock JM, Ledent C, Petzold A, Thompson AJ, Giovannoni G, Cuzner ML, Baker D (2003) Cannabinoids inhibit neurodegeneration in animal models of multiple sclerosis. Brain 126:2191-2102.
62. Ramirez BG, Blazquez C, Gomez del Pulgar T, Guzman M, de Caballos ML (2005) Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neurosci 25:1904-1913.
63. Rueda D, Navarro B, Martinez-Serrano A, Guzmán M, Galve-Roperh I (2002) The endocannabinoid anandamide inhibits neuronal progenitor cell differentiation through attenuation of the Rap1/B-Raf/ERK pathway. J Biol Chem 277:46645-46650.
64. 9-Tetrahydrocannabinol induces apoptosis in C6 glioma cells. FEBS Lett 436:6-10.
65. 2 cannabinoid receptors expressed in prostate PC-3 cells. Involvement in Raf-1 stimulation and NGF induction. Cell Signal 15:851-859.
66. Sarker KP, Biswas KK, Yamakuchi M, Lee K-Y, Hahiguchi T, Krach M, Kitajima I, Maruyama I (2003) ASK1-p38 MAPK/JNK signaling cascade mediates anandamide-induced PC12 cell death. J Neurochem 85:50-61.
67. Scallet AC, Uemura E, Andrews A, Ali SF, McMillan DE, Paule MG, Brown RM, Slikker W (1987) Morphometric studies of the rat hippocampus following chronic delta-9-tetrahydrocannabinol (THC). Brain Res 436:193-198.
68. Scallet AC (1991) Neurotoxicology of cannabis and THC: A review of chronic exposure studies in animals. Pharm Biochem Behav, 40:671-676.
69. Schlaepfer TE, Lancaste E, Heidbreder R, Strain EC, Kosel M, Fisch HU, Pearlson GD (2006) Decreased frontal white-matter volume in chronic substance abuse. Int J Neuropsychopharmacol 9:147-153.
70. Shen M, Piser TM, Seybold VS, Thayer SA (1996) Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures. J Neurosci 16:4322-4334.
71. Shen M, Thayer SA (1998) The cannabinoid agonist Win55, 212-2 inhibits calcium channels by receptor-mediated and direct pathways in cultured rat hippocampal neurons. Brain Res 783:77-84.
72. Sinor AD, Irvin SM, Greenberg DA (2000) Endocannabinoids protect cerebral cortical neurons from in vitro ischemia in rats. Neurosci Lett 278:157-160.
73. Sommer C, Schomacher M, Berger C, Kuhnert K, Muller HD, Schwab S, Schabitz WR (2006) Neuroprotective cannabinoid receptor antagonist SR141716A prevents downregulation of excitotoxic NMDA receptors in the ischemic penumbra. Acta Neuropathol 112:277-286.
74. Stella N, Schweitzer P, Piomelli D (1997) A second endogenous cannabinoid that modulates longterm potentiation. Nature 388:773-778.
75. Tagliaferro P, Javier Ramos A, Onaivi ES, Evrard SG, Lujilde J, Brusco A (2006) Neuronal cytoskeleton and synaptic densities are altered after a chronic treatment with the cannabinoid receptor agonist WIN 55, 212-2. Brain Res 1085:163-176.
76. 1 cannabinoid receptor mediates glutamatergic synaptic suppression in the hippocampus. Neuroscience 139:795-802.
77. Twitchell W, Brown S, Mackie K (1997) Cannabinoids inhibit N- And P/Q-type calcium channels in cultured rat hippocamapl neurons. J Neurophysiol 78:43-50.
78. Tzilos GK, Cintron CB, Wood JB, Simpson NS, Young AD, Pope HG, Yurgelun-Todd DA (2005) Lack of hippocampal volume change in long-term cannabis users. Am J Addict 14:64-72.
79. Van Der Stelt M, Veldeheis WB, Bar PR, Veldink GA, Vliegenthart JFG, Nicolay K (2001) Neuroprotection by δ9-Tetrahydrocannabinol, the main active compound in marijuana, against ouabain-induced in vivo excitotoxicity. J Neurosci, 21:6475-6479.
80. Williams EJ, Walsh FS, Doherty P (2003) The FGF receptor uses the endocannabinoid signalling system to couple to an axonal growth response. J Cell Biol 160:481-486.
81. Zhunag S-Y, Bridges D, Grigoenko E, McCloud S, Boon A, Hampson RE, Deadwyler SA (2005) Cannabinoids produce neuroprotection by reducing intracellular calcium release from ryanodine- sensitive stores. Neuropharmacol 28:1086-1096.